Literature DB >> 2765789

Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.

E A Kiely1, S R Bloom, G Williams.   

Abstract

Intracavernosally injected vasoactive intestinal polypeptide (VIP) (2 micrograms and 4 micrograms) resulted in penile tumescence even in men with predominantly organic impotence. Papaverine and phentolamine were successful in inducing erections in all subjects studied but the addition of VIP to this combination improved the erectile response further. A combination of papaverine and VIP produced penile rigidity similar to that with papaverine and phentolamine. While intracavernosal VIP alone produced disappointing penile responses, its combination with papaverine potentiated the response to this drug, probably by increasing venous outflow resistance.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2765789     DOI： 10.1111/j.1464-410x.1989.tb05986.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN： 0007-1331


  9 in total

Review 1.  Drugs for the treatment of impotence.

Authors:  L Garcia-Reboll; J P Mulhall; I Goldstein
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 2.  Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings.

Authors:  K E Andersson; F Holmquist
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 3.  Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.

Authors:  Stephen L Archer; Ferrante S Gragasin; Linda Webster; Derek Bochinski; Evangelos D Michelakis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Intracavernous pharmacotherapy.

Authors:  M C Truss; A J Becker; D Schultheiss; U Jonas
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

5.  Penile erections induced by vasoactive intestinal peptide and sodium nitroprusside.

Authors:  R Wang; T R Higuera; S C Sikka; R K Minkes; J A Bellan; P J Kadowitz; F R Domer; W J Hellstrom
Journal:  Urol Res       Date:  1993-01

6.  Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum.

Authors:  P Hedlund; P Alm; P Ekström; J Fahrenkrug; J Hannibal; H Hedlund; B Larsson; K E Andersson
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 7.  Impotence in elderly men.

Authors:  J E Morley; F E Kaiser
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

Review 8.  Oral and injectable medications for the treatment of erectile dysfunction.

Authors:  C C Carson
Journal:  Curr Urol Rep       Date:  2000-12       Impact factor: 2.862

Review 9.  Intracavernous pharmacotherapy for erectile dysfunction.

Authors:  Anthony J Bella; Gerald B Brock
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.925
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.